Malignant Mesothelioma
Malignant mesothelioma (MM) is a rare and aggressive cancer, related to chronic inflammation and oxidative stress caused mainly by exposure to asbestos. Although this mineral has been banned for decades in many countries, epidemiologists predict the MM epidemic will last past 2040, raising many conc...
Gardado en:
| Formato: | Online |
|---|---|
| Idioma: | inglés |
| Publicado: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Subjects: | |
| Acceso en liña: | ONIX_20220111_9783036523682_878 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|
| _version_ | 1869516368670359552 |
|---|---|
| collection | Directory of Open Access Books |
| description | Malignant mesothelioma (MM) is a rare and aggressive cancer, related to chronic inflammation and oxidative stress caused mainly by exposure to asbestos. Although this mineral has been banned for decades in many countries, epidemiologists predict the MM epidemic will last past 2040, raising many concerns in public health given its late diagnosis, dismal prognosis, and lack of current efficient therapies.To deal with this situation, important breakthroughs have recently been made in the understanding of MM’s complex biology and the carcinogenic process of the different patterns of the disease. Examples of these include the development of new biomarkers and the deciphering of gene–environment interactions, molecular mechanisms of invasiveness, deregulated pathways, altered expression of miRNAs, DNA damage repair, or metabolic profile. From now on, MM’s aggressive and chemoresistant character appears linked to a polyclonal malignancy, and heterogeneity in molecular alterations.Given these improvements, new therapeutic targets are being explored to solve the double challenge faced by clinicians. The first is to reduce tumor development and its wasting consequences as soon as possible, without resistance and with limited toxicity. The second is to stimulate the recognition of tumor cells by the induction of a specific immune response. This Special Issue will highlight all these aspects. |
| format | Online |
| id | doab-20.500.12854ir-77046 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-770462024-03-30T23:21:53Z Malignant Mesothelioma L. Pouliquen, Daniel Kopecka, Joanna well-differentiated papillary mesothelioma WDPM malignant mesothelioma DNA sequencing mutation mesothelioma tumor suppressor targeted therapy immunotherapy biomarkers proteomics macrophage-capping protein fatty acid-binding protein laminin subunit beta-2 selenium-binding protein 1 carcinogenesis malignant pleural mesothelioma asbestos exposure DNA methylation lymphocyte-to-monocyte ratio epigenome-wide analysis survival analysis metabolomics radiotherapy cancers inflammation infiltrating immune cells prognostic biomarker predictive biomarker immune therapy VATS extrapleural pneumonectomy pleurectomy decortication therapy response survival FDG PET-CT mesothelium oxidative stress redox-sensitive factors asbestos carbon nanotubes protein-protein interactions systems biology network analysis drug repurposing pleural mesothelioma gene expression immunogenicity sarcomatoid epithelioid first line meta-analysis systematic review MPM lurbinectedin DNA damage response histotype Hippo pathway NF2 BAP1 CDKN2A PTCH1 SETD2 MTAP liquid biopsies circulating tumor DNA plasma cancer-specific mutations genomics cancer biomarkers tumor microenvironment tumor-associated macrophages dendritic cells immunohistochemistry interaction analysis pleural effusion n/a thema EDItEUR::M Medicine and Nursing Malignant mesothelioma (MM) is a rare and aggressive cancer, related to chronic inflammation and oxidative stress caused mainly by exposure to asbestos. Although this mineral has been banned for decades in many countries, epidemiologists predict the MM epidemic will last past 2040, raising many concerns in public health given its late diagnosis, dismal prognosis, and lack of current efficient therapies.To deal with this situation, important breakthroughs have recently been made in the understanding of MM’s complex biology and the carcinogenic process of the different patterns of the disease. Examples of these include the development of new biomarkers and the deciphering of gene–environment interactions, molecular mechanisms of invasiveness, deregulated pathways, altered expression of miRNAs, DNA damage repair, or metabolic profile. From now on, MM’s aggressive and chemoresistant character appears linked to a polyclonal malignancy, and heterogeneity in molecular alterations.Given these improvements, new therapeutic targets are being explored to solve the double challenge faced by clinicians. The first is to reduce tumor development and its wasting consequences as soon as possible, without resistance and with limited toxicity. The second is to stimulate the recognition of tumor cells by the induction of a specific immune response. This Special Issue will highlight all these aspects. 2022-01-11T13:50:24Z 2022-01-11T13:50:24Z 2021 book ONIX_20220111_9783036523682_878 9783036523682 9783036523675 https://directory.doabooks.org/handle/20.500.12854/77046 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/4656 https://mdpi.com/books/pdfview/book/4656 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-2367-5 10.3390/books978-3-0365-2367-5 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036523682 9783036523675 328 Basel, Switzerland open access |
| spellingShingle | well-differentiated papillary mesothelioma WDPM malignant mesothelioma DNA sequencing mutation mesothelioma tumor suppressor targeted therapy immunotherapy biomarkers proteomics macrophage-capping protein fatty acid-binding protein laminin subunit beta-2 selenium-binding protein 1 carcinogenesis malignant pleural mesothelioma asbestos exposure DNA methylation lymphocyte-to-monocyte ratio epigenome-wide analysis survival analysis metabolomics radiotherapy cancers inflammation infiltrating immune cells prognostic biomarker predictive biomarker immune therapy VATS extrapleural pneumonectomy pleurectomy decortication therapy response survival FDG PET-CT mesothelium oxidative stress redox-sensitive factors asbestos carbon nanotubes protein-protein interactions systems biology network analysis drug repurposing pleural mesothelioma gene expression immunogenicity sarcomatoid epithelioid first line meta-analysis systematic review MPM lurbinectedin DNA damage response histotype Hippo pathway NF2 BAP1 CDKN2A PTCH1 SETD2 MTAP liquid biopsies circulating tumor DNA plasma cancer-specific mutations genomics cancer biomarkers tumor microenvironment tumor-associated macrophages dendritic cells immunohistochemistry interaction analysis pleural effusion n/a thema EDItEUR::M Medicine and Nursing Malignant Mesothelioma |
| title | Malignant Mesothelioma |
| title_full | Malignant Mesothelioma |
| title_fullStr | Malignant Mesothelioma |
| title_full_unstemmed | Malignant Mesothelioma |
| title_short | Malignant Mesothelioma |
| title_sort | malignant mesothelioma |
| topic | well-differentiated papillary mesothelioma WDPM malignant mesothelioma DNA sequencing mutation mesothelioma tumor suppressor targeted therapy immunotherapy biomarkers proteomics macrophage-capping protein fatty acid-binding protein laminin subunit beta-2 selenium-binding protein 1 carcinogenesis malignant pleural mesothelioma asbestos exposure DNA methylation lymphocyte-to-monocyte ratio epigenome-wide analysis survival analysis metabolomics radiotherapy cancers inflammation infiltrating immune cells prognostic biomarker predictive biomarker immune therapy VATS extrapleural pneumonectomy pleurectomy decortication therapy response survival FDG PET-CT mesothelium oxidative stress redox-sensitive factors asbestos carbon nanotubes protein-protein interactions systems biology network analysis drug repurposing pleural mesothelioma gene expression immunogenicity sarcomatoid epithelioid first line meta-analysis systematic review MPM lurbinectedin DNA damage response histotype Hippo pathway NF2 BAP1 CDKN2A PTCH1 SETD2 MTAP liquid biopsies circulating tumor DNA plasma cancer-specific mutations genomics cancer biomarkers tumor microenvironment tumor-associated macrophages dendritic cells immunohistochemistry interaction analysis pleural effusion n/a thema EDItEUR::M Medicine and Nursing |
| topic_facet | well-differentiated papillary mesothelioma WDPM malignant mesothelioma DNA sequencing mutation mesothelioma tumor suppressor targeted therapy immunotherapy biomarkers proteomics macrophage-capping protein fatty acid-binding protein laminin subunit beta-2 selenium-binding protein 1 carcinogenesis malignant pleural mesothelioma asbestos exposure DNA methylation lymphocyte-to-monocyte ratio epigenome-wide analysis survival analysis metabolomics radiotherapy cancers inflammation infiltrating immune cells prognostic biomarker predictive biomarker immune therapy VATS extrapleural pneumonectomy pleurectomy decortication therapy response survival FDG PET-CT mesothelium oxidative stress redox-sensitive factors asbestos carbon nanotubes protein-protein interactions systems biology network analysis drug repurposing pleural mesothelioma gene expression immunogenicity sarcomatoid epithelioid first line meta-analysis systematic review MPM lurbinectedin DNA damage response histotype Hippo pathway NF2 BAP1 CDKN2A PTCH1 SETD2 MTAP liquid biopsies circulating tumor DNA plasma cancer-specific mutations genomics cancer biomarkers tumor microenvironment tumor-associated macrophages dendritic cells immunohistochemistry interaction analysis pleural effusion n/a thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20220111_9783036523682_878 |